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Abstract
Background and aim Fat mass generation requires an energy surplus and
the activity of the peroxisome proliferator-activated receptor γ (PPARγ ). We
investigated if the PPARγ ligand rosiglitazone influences substrate usage,
energy expenditure (EE) and energy intake (EI) and, thereby, how PPARγ
activity contributes to susceptibility to obesity.
Methods Twenty healthy males (20–29 years) were randomly assigned to
receive a placebo (n = 10) or rosiglitazone (8 mg/d) (n = 10) for seven
consecutive days, while staying in a respiration chamber. Food intake was
ad libitum. Body composition was determined by underwater weighing (day
1) and deuterium dilution (day 1 and 8).
Results Mean (±SE) EI was 15.9 ± 0.9 MJ/d in the placebo group and
18.9 ± 1.2 MJ/d in the rosiglitazone group. Mean EE was 11.3 ± 0.3 MJ/d
and 12.5 ± 0.5 MJ/d for the placebo and rosiglitazone groups respectively.
This resulted in a cumulative positive energy balance (EB) of 32.3 ± 5.1 MJ
for placebo and 44.7 ± 6.9 MJ for rosiglitazone. There were no significant
differences in EI, EE, and EB between treatments. Both groups did not adjust
their fat oxidation to the increased fat intake, but fat oxidation decreased
faster in the rosiglitazone group (significantly lower on days 6 and 7).
During treatment with rosiglitazone, significantly more fat storage was seen
in overweight subjects while this was not the case in the placebo group.
Conclusions Our results suggest a shift in substrate usage during PPARγ
stimulation leading to a preference for fat storage, especially in subjects with
a higher BMI. Copyright  2005 John Wiley & Sons, Ltd.
Keywords peroxisome proliferator-activated receptor γ ; substrate usage; energy
expenditure; energy intake; energy storage; humans
Introduction
Obesity develops when energy intake (EI) exceeds energy expenditure (EE)
for longer periods. Excess energy is stored in the main energy storing tissue,
the adipose tissue. The adipocyte is not only an important mediator of energy
metabolism by storing excess energy as fat, but also by secreting adipokines
involved in energy metabolism, like leptin, adiponectin and resistin [1].
Fat mass generation requires an energy surplus and the activity of the
peroxisome proliferator-activated receptor γ (PPARγ ), a transcription factor
that is expressed at high levels in adipose tissue, and at lower levels in the
skeletal muscle, liver and heart [2,3]. Dominant-negative PPARγ mutations
lead to partial lipodystrophy [4], while dominant-positive PPARγ mutations
Copyright  2005 John Wiley & Sons, Ltd.
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are associated with severe obesity [5]. PPARγ is a
key factor in fat metabolism as it is required for
adipogenesis, the differentiation of preadipocytes into
mature adipocytes, and has an important role in fat
storage [6]. PPARγ is a member of the nuclear hormone
receptor family whose transcriptional activity is regulated
by the formation of heterodimers and the binding of
ligands [7]. Natural ligands include polyunsaturated fatty
acids and eicosanoids [8]. Potent synthetic ligands include
the anti-diabetic thiazolidinedione (TZD) class of drugs
[9]. TZDs are widely and effectively used in the treatment
of type 2 diabetes mellitus for their insulin-sensitizing
effects [9]. However, treatment with TZD is accompanied
by weight gain in rodents [10] and obese, diabetic patients
[11]. Though fluid retention is a known side effect of TZD
treatment [12], the major part of the weight gain consists
of fat [10] which does suggest an effect of PPARγ on
energy balance (EB) regulation as fat gain will only occur
in the presence of an energy surplus. Indeed, PPARγ
activation in lean rats, in diet-induced obese rats, and
in insulin-resistant fatty Zucker rats resulted in weight
gain because of both an increased food intake and an
improved feed efficiency [13–15]. On the other hand,
pair-feeding of chow-fed rats and dietary obese rats
to prevent hyperphagia prevented rosiglitazone-related
weight gain in chow-fed rats, though this was not the case
with the dietary obese rats [13]. Similar results were
observed in humans. Obese, diabetic patients treated
with TZD, who reported weight gain following TZD
treatment, effectively lost weight with caloric restriction
and increased physical activity [11]. These observations
emphasize a possible role for PPARγ in the regulation of
EI and expenditure. We hypothesized that stimulation of
PPARγ with the PPARγ ligand rosiglitazone in healthy,
normal to overweight men would induce susceptibility to
weight gain by affecting substrate usage, EE and EI.
Subjects and methods
Subjects
Subjects were recruited through noticeboards in the
university and in the university hospital. Subjects had to
be male, between the age of 18 and 40 years, Caucasian,
healthy and have a body mass index (BMI) between 20
and 32 kg/m2. They had to be unrestrained eaters, as
indicated by the Three-Factor Eating Questionnaire [16]
with scores ≤ 9 on Factor 1 (cognitive restraint). Subjects
completed a medical questionnaire before entering the
study; only subjects in good health were included.
Subjects who followed a dietary regime with the aim
to lose or gain weight within a year prior to the study
were excluded. The study design required that the subjects
were not fully informed about the adipogenic effect of the
PPARγ agonist rosiglitazone as this could influence self-
selected food and EI and activity-induced EE. Therefore,
subjects were told that they would receive either a
substance that influences fat metabolism or a non-active
Table 1. Baseline characteristics of the subjects
Placebo (n = 10) Rosiglitazone (n = 10)
Mean SE Mean SE
Age (years) 22 1 24 1
Height (m) 1.83 0.02 1.84 0.02
Body weight (kg) 80.2 3.5 85.7 3.6
BMI (kg/m2) 24.0 1.3 25.1 0.7
Body fat (%) 19.6 1.9 20.3 2.4
Cognitive restraint scorea 5 1 4 1
aFactor 1 of the three-factor eating questionnaire [16].
substance (placebo) in a double-blind manner (i.e. neither
the subject nor the investigator knew what the subject
received during the experiment). The study was approved
by the Ethics Committee of Maastricht University. All
subjects received verbal and written information and
signed a written consent form. Twenty men between
the age of 20 and 29 years participated in the study.
Characteristics of the subjects are shown in Table 1.
Experimental design
Subjects were studied during a stay in a respiration
chamber for seven consecutive days for EE and
substrate oxidation measurements. Following a double-
blind, placebo-controlled design, subjects were randomly
assigned to receive either 8 mg/d rosiglitazone (Avandia,
GlaxoSmithKline BV, The Netherlands) or a placebo
orally. Drugs were dosed twice daily for the total stay
of 7 days in the respiration chamber. Subjects were asked
to eat ad libitum from an excess of food supplied at
each mealtime and as snacks. No exercise protocol was
imposed, but sleeping during daytime and strenuous
physical activity were not allowed. Subjects were woken
up between 08 : 00 and 08 : 30 h, and they were free to
choose their bedtime in the evening. Body composition
was determined by underwater weighing and deuterium
dilution (day 1) or by deuterium dilution alone (day 8).
On the same days, blood samples were taken.
Dietary intake
Meals consisting of typically Dutch food items were
provided three times per day, breakfast between 08 : 30
and 09 : 00 h, lunch between 12 : 30 and 13 : 00 h, and
dinner between 18 : 00 and 18 : 30 h. Breakfast and lunch
consisted of bread, savoury and sweet condiments, fruit,
yogurt, milk, fruit juice, instant coffee (decaffeinated)
and tea. For dinner, subjects could choose between
ready-prepared potato-, pasta- or rice-based meals with
only vegetables or with vegetables plus meat or fish.
They were allowed two alcoholic consumptions, white
or red wine or beer, per day. A wide variety of snacks
was continuously available in the chamber in packages
that were refreshed every morning. Snacks consisted of
savoury items (crisps, nuts), sweet items (chocolate bars,
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sweets), various biscuits, fruit (apple, orange, banana),
instant soup, fruit juice, instant coffee (decaffeinated)
and tea. Meals and snacks were supplied in excess to be
eaten ad libitum; extra food items were readily available
on request. All foods and drinks entering and leaving the
respiration chamber were weighed to the nearest gram.
Energy content and macronutrient composition of the
diets were calculated using the Dutch food composition
table (NEVO 1996).
Procedures
Anthropometry and body composition
Measurements were carried out in the morning after
voiding and before breakfast. Body weight and height
were measured to the nearest 0.01 kg and 0.1 cm
respectively. Body mass index (BMI, kg/m2) was
calculated as body weight (kg) divided by height
(m) squared. Body density was determined by underwa-
ter weighing with simultaneous measurement of resid-
ual lung volume with the helium dilution technique.
Total body water (TBW) was determined with deu-
terium dilution following the Maastricht protocol [17].
Body composition was calculated from body density
and TBW using the three-compartment model of Siri
[18].
Energy expenditure
EE was measured in the respiration chamber [19] from
oxygen consumption, carbon dioxide production and
urinary nitrogen excretion according to the formula
of Brouwer [20]. The respiration chamber measured
14 m3 and was furnished with a bed, chair, table, TV,
radio, telephone, computer, washbowl and toilet facilities
[19].
Substrate oxidation
Carbohydrate (CHO), fat (F) and protein (P) oxidation
was calculated from oxygen consumption, carbon diox-
ide production and urinary nitrogen excretion. As sub-
jects were allowed to have maximally two alcoholic
consumptions per day, oxygen consumption and car-
bon dioxide production on these days were first cor-
rected for alcohol intake, assuming that all alcohol
ingested was oxidized, before calculation of CHO, F
and P oxidation according to the formula of Brouwer
[20].
P oxidation (g/d) = 6.25 ∗ N
F oxidation (g/d) = 1.718 ∗ VO2 − 1.718 ∗ VCO2
− 0.315 ∗ P
CHO oxidation (g/d) = 4.17 ∗ VCO2 − 2.965 ∗ VO2
− 0.390 ∗ P
with:
N = total nitrogen excreted in urine (g/d)
VO2 = oxygen consumption (l/d), corrected for alcohol
intake
VCO2 = carbon dioxide production (l/d), corrected for
alcohol oxidation
P = protein oxidation (g/d)
24-h urine was collected from the second void-
ing of the day until the first voiding of the follow-
ing day. 24-h urines were collected for each of the
7 days in the respiration chamber separately. Urine
bottles contained 10 ml H2SO4 to prevent nitrogen
loss through evaporation. Volume and nitrogen con-
centration were measured, the latter using a nitro-
gen analyser (Elemental Analyser, CHN-O-Rapid, Her-
aeus).
Carbohydrate and fat balances were calculated as
intake minus oxidation of each macronutrient. The pro-
tein balance was calculated as [N intake − (urinary N +
faecal N)] ∗ 6.25, assuming an average daily value of
3 g/d for faecal N loss [21].
Blood parameters
After an overnight fast, blood samples were obtained
and mixed with citrate to prevent clotting. Plasma was
obtained by centrifugation (4 ◦C, 3000 rpm, 10 min),
frozen in liquid nitrogen and stored at −80 ◦C until
analysis of concentrations of glucose (hexokinase method,
Glucose HK 125 kit, ABX Diagnostics, Montpellier,
France), insulin (ELISA, Mercodia, Uppsala, Sweden),
leptin (double-antibody RIA, human leptin specific
RIA kit, Linco Research Inc., St Charles, USA) and
triacylglycerols (TAGs) (Triglycerides liquicolor kit,
Instruchemie, Delfzijl, The Netherlands).
Statistical analysis
Results are presented as mean ± standard error (SE).
Differences between treatments were analysed with one-
way analysis of variance (ANOVA) or the Mann-Whitney
U-test (blood parameters). Interaction between treatment
and body weight class for fat balance was analysed with an
univariate ANOVA with treatment and body weight class
as fixed factors. Measurements at baseline and at the end
of the experiment were compared with Student’s paired
t-test (two-tailed) or Wilcoxon’s paired signed rank test
(blood parameters). P < 0.05 was considered statistically
significant. SPSS 11 for Macintosh (SPSS Inc., Chicago,
IL, 2002) was used for the analysis.
Results
Energy intake and expenditure
The mean daily EI was 15.9 ± 0.9 MJ/d for placebo and
18.9 ± 1.2 MJ/d for rosiglitazone, which was not signif-
icantly different (P = 0.06). Mean daily macronutrient
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composition was not significantly different between
treatments, except for CHO intake, which was higher
in the rosiglitazone group (P < 0.05).
Similar results were obtained for EE and macronutrient
oxidation. EE was not significantly different between
treatments (P = 0.09) with mean daily values of
11.3 ± 0.3 MJ/d for placebo and 12.5 ± 0.5 MJ/d for
rosiglitazone. Mean daily macronutrient oxidation was
not significantly different between treatments, except for
CHO oxidation, which was higher in the rosiglitazone
group (P < 0.05).
Energy balance
Energy balance (EB) was calculated as the difference
between EI and EE. Figure 1 shows that cumulative EB
increased from day 1 to day 7 on both treatments. By
the end of day 7, cumulative EB was 32.3 ± 5.1 MJ
for placebo and 44.7 ± 6.9 MJ for rosiglitazone. This
differed significantly from zero on both treatments
(P < 0.001), but was not significantly different between
treatments (P = 0.16). The positive EB was reflected
in changes in body weight. Body weight increased by
1.39 ± 0.37 kg (P < 0.01) in the placebo group and by
2.54 ± 0.53 kg (P = 0.001) in the rosiglitazone group.
Changes in body weight did not differ significantly
between treatments (P = 0.09). However, body weight
change on rosiglitazone was associated with an increase
in TBW of 1.6 ± 0.6 l (P < 0.05), whereas TBW did not
significantly change in the placebo group (−0.2 ± 0.7 l,
P = 0.79). The difference in TBW change was not
significantly different between treatments (P = 0.06).
The cumulative nutrient balances are shown in
Figures 2(a),(b) and (c). The cumulative protein balance
became more positive from day 1 to 7 in both groups
(Figure 2a). Total protein balance by the end of day 7 was
significantly different from zero for rosiglitazone (1.6 ±
0.5 MJ; P < 0.01), but not for placebo (1.0 ± 0.6 MJ;
P = 0.10). Total protein balance was not significantly
different between treatments (P = 0.47).
Figure 1. Mean (±SE) cumulative energy balance (MJ) for the
placebo (♦) and rosiglitazone () groups on days 1–7
From day 1 to 4 the cumulative carbohydrate balance
increased, but then decreased from day 5 indicating an
adaptation of carbohydrate oxidation to carbohydrate
intake (Figure 2b). By the end of day 7, total carbohydrate
balance was not significantly different from zero for
both the placebo (0.8 ± 1.8 MJ, P = 0.65) and the
rosiglitazone groups (−0.2 ± 1.5 MJ, P = 0.90). There
was no significant effect of treatment on the carbohydrate
balance (P = 0.67).
The total EB was for both treatments mainly determined
by the fat balance. The cumulative fat balance gradually
increased from day 1 to 7 (Figure 2c). By the end of
day 7, the cumulative fat balance was 29.5 ± 4.9 MJ
(P < 0.001) for placebo and 42.3 ± 6.8 MJ (P = 0.00) for
rosiglitazone. Although this was not significantly different
between the treatments (P = 0.14), the pattern of fat
intake and fat oxidation differed. Figure 3 shows that
both groups did not adjust their fat oxidation to the
increased fat intake. However, fat oxidation decreased
faster in the rosiglitazone group and by day 6 and 7, fat
oxidation was significantly lower compared to placebo.
Individual fat balances all increased similarly in the
placebo group, independent of the classification normal
weight (BMI < 25 kg/m2, solid lines) or overweight (BMI
≥ 25 kg/m2, dotted lines) (Figure 4a). However, there
was a significant interaction between body weight class
and treatment (P < 0.001). As can be seen in Figure 4(b),
during treatment with rosiglitazone overweight subjects
stored more fat than normal weight subjects.
Blood parameters
Table 2 shows the mean fasting plasma concentrations
of glucose, insulin, leptin and TAGs. In the placebo
group, plasma glucose was decreased and TAGs were
increased after overfeeding, other parameters did not
change significantly. In the rosiglitazone group, plasma
insulin and TAGs were increased after overfeeding,
plasma glucose and leptin did not change significantly.
There was a significant treatment effect on changes in
plasma glucose (P = 0.02) and TAGs (P = 0.03), but not
on plasma insulin (P = 0.07) and leptin (P = 0.15).
Table 2. Fasting plasma parameters at baseline and after
self-induced overfeeding for the placebo and rosiglitazone
treated groups
Placebo (n = 10) Rosiglitazone (n = 10)
Baseline Overfeeding Baseline Overfeeding
mean SE mean SE mean SE mean SE
Glucose (mmol/l) 5.0 0.1 4.6a 0.1 4.8 0.1 4.9 0.2
Insulin (µU/ml) 7.8 0.6 8.5 0.5 6.0 0.8 8.2b 1.1
Leptin (ng/ml) 5.4 1.1 5.6 1.0 5.6 1.4 5.3 1.4
TAG (mmol/l) 0.6 0.04 1.2a 0.2 0.8 0.1 2.5a 0.7
TAG = triacylglycerol
aSignificantly different from baseline (within-group) using Wilcoxon’s
paired signed rank test P < 0.01.
bP = 0.01.
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Figure 2. Mean (±SE) cumulative protein (a), carbohydrate (b) and fat (c) balances (MJ) for the placebo (♦) and rosiglitazone ()
groups on days 1–7
Figure 3. Mean (±SE) fat intake (dotted lines) and fat oxidation
(solid lines) (g) for placebo (♦) and rosiglitazone () groups
on days 1–7. ∗P = 0.05,∗∗P < 0.05 oxidation between groups
(one-way ANOVA)
Discussion
The increasing prevalence of obesity is related to
changing dietary habits and a sedentary lifestyle [22].
The contribution of environmental factors is apparent,
but genetic factors are also involved [23]. PPARγ is
a key regulator of fat metabolism; therefore, a high
PPARγ activity could form a predisposing factor for
the excess of fat mass characteristic for obesity. The
present study aimed to investigate the influence of the
PPARγ ligand rosiglitazone on substrate usage, EE and
EI. Twenty males were studied during a 7-day stay in the
respiration chamber. During this period, PPARγ activity
was stimulated with rosiglitazone in ten males; the control
group received a placebo treatment.
As shown before [24,25], the sedentary lifestyle
imposed by the restrictions of the small environment
in the respiration chamber together with an ad libitum
food intake resulted in a significant positive EB by the
end of day 7 in both groups. Though not statistically
significant, there was a trend towards an effect of PPARγ
stimulation on EB regulation. EI tended to be higher in the
rosiglitazone treated group, similar to results observed
in lean rats, in diet-induced obese rats, and in insulin-
resistant fatty Zucker rats treated with TZD, where an
increased weight gain was associated with increased
food intake and feed efficiency [13–15]. Theoretically,
PPARγ can influence food intake through a direct effect
on the central nervous system or indirectly through
effects on peripheral tissues. In humans, PPARγ is most
abundantly expressed in adipose tissue and at lower levels
in skeletal muscle, liver and heart [2,3]. It is therefore
most likely that the tendency to increase food intake with
Copyright  2005 John Wiley & Sons, Ltd. Diabetes Metab Res Rev 2006; 22: 204–210.
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Figure 4. Individual cumulative fat balances (g) for the placebo
(a) and rosiglitazone (b) groups. Solid lines represent subjects
with BMI < 25 kg/m2, dotted lines represent subjects with BMI
≥ 25 kg/m2
rosiglitazone is because of the PPARγ activity in adipose
tissue. The adipokine leptin is known to be a regulator of
EI and expenditure [1], and plasma leptin concentrations
can be decreased in lean and diet-induced rats with
PPARγ stimulation [13]. However, plasma leptin was not
decreased in ad libitum-fed rats treated with rosiglitazone
and could thus not explain the observed hyperphagia
[13]. Similarly, plasma leptin did not change on either
treatment and is therefore unlikely to have influenced
food intake or thermogenesis in our subjects.
There was no statistical significant effect of PPARγ
stimulation on EE, indicating no thermogenic dissipation
of the excess energy. However, when we look at nutrient
oxidation, there was an effect on fat oxidation after 6 days
of rosiglitazone treatment. Both groups could not adjust
their fat oxidation to fat intake during the 7-day treatment
period, but treatment with rosiglitazone worsened the
adaptation of fat oxidation to fat intake. Independent
of treatment, the majority of excess energy was stored
as fat, as can be expected from the limited storage
capacity for carbohydrates which forces an increase
in carbohydrate oxidation to maintain carbohydrate
balance. In addition, the positive fat balances seen
in the majority of the subjects developed faster in
overweight subjects compared to normal weight subjects
treated with rosiglitazone. Smith et al. [26] found similar
results in obese type 2 diabetic patients treated with
another TZD, pioglitazone (45 mg/d), for 24 weeks.
Though not statistically significant, substrate oxidation
after a meal tended towards fat storage and an increased
carbohydrate oxidation. Pioglitazone treatment resulted
in fat gain, but this change could not be accounted for,
as measurements of 24-h EE and EI were not included.
In contrast, Füllert et al. [27] did not find an increase
in body weight in overweight, non-diabetic patients with
arterial hypertension treated with 45 mg/d pioglitazone
for 16 weeks.
Furthermore, overfeeding resulted in increased fasting
plasma TAG concentrations in both groups, but this
increase was significantly higher with PPARγ stimulation.
As fasting plasma TAGs and fat oxidation have been shown
to predict weight gain in diet-induced prone and resistant
rats [28], this indicates an insufficient fat oxidation and
a tendency to retain TAGs in the plasma until storage in
the adipose tissue. However, PPARγ activation during ad
libitum feeding, initiating a positive EB, resulted in lower
plasma TAGs in db/db mice, fatty Zucker rats [10], ob/ob
mice [29] and diet-induced mice [14] but not in lean
mice [29], which suggests that fat storage upon PPARγ
activation is only accompanied by a decrease in plasma
TAGs if baseline values are already elevated.
The favourable effects of TZD treatment on plasma glu-
cose and insulin concentrations in type 2 diabetic patients
are attributed to their ability to stimulate PPARγ [9].
However, in our group of healthy, normal to overweight
men, overfeeding induced a significant increase in plasma-
insulin concentrations with PPARγ stimulation. Probably,
TZD treatment is only associated with decreased insulin in
patients already showing elevated plasma concentrations.
This was also seen in patients with type 1 diabetes, where
the greatest improvements in glycemic control with com-
bined rosiglitazone and insulin treatment were seen in
those patients with more pronounced markers of insulin
resistance [30].
Though PPARγ activity in adipose tissue is necessary
to convert an energy surplus into fat mass, PPARγ
does play an important role in liver and muscle fat
metabolism as well. Adipose-specific PPARγ knockout
mice are lipodystrophic, leading to decreased plasma
leptin and increased plasma TAG concentrations, storage
of fat in skeletal muscle and liver, and increased hepatic
PPARγ mRNA [31]. Hepatic PPARγ plays a critical
role in the regulation of TAG content, blood glucose
homeostasis and insulin resistance as liver-specific PPARγ
knockout mice have a diabetic phenotype including an
increased adiposity [32,33]. PPARγ knockout in muscle,
the major site of fat oxidation, causes an impaired
ability of muscle to use fat and thus shunting of fat
to the liver, increased adiposity and hepatic insulin
resistance. Our results indicate that healthy men treated
with rosiglitazone develop an insulin-resistant state, with
increased plasma TAG and insulin concentrations, which
facilitates the development of a positive fat balance. The
observation that overweight subjects develop a positive
fat balance faster than do normal weight subjects supports
this hypothesis, as overweight subjects are generally
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considered to be obesity-prone. We expect that these
effects will be more pronounced when rosiglitazone
treatment continues for longer periods as it might take
more than 7 days for full effects on plasma parameters
to develop. In addition, fat oxidation gradually became
more suppressed compared to the placebo group from
day 6, which might have been earlier if rosiglitazone
treatment was already started before the respiration
chamber measurements. Yet, TBW was significantly
increased in the rosiglitazone group, which indicates
that rosiglitazone exerted effects on metabolism within
7 days.
In summary, our results suggest a shift in substrate
usage during PPARγ stimulation leading to a pref-
erence for fat storage, especially in subjects with a
higher BMI.
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